Dear Sir, Please find the attachment. Regards, For MRC Agrotech Limited Compliance Officer / Authorised Signatory
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
MRC Agrotech has revised the use of proceeds from its upcoming preferential issue, totalling Rs. 428.59 lakhs. The company has dropped the earlier 'repayment of borrowings' head, confirming that all outstanding short-term obligations were already cleared from internal accruals before June 2025. The revised allocation is Rs. 313.30 lakhs for working capital (raw materials, supplier payments, distributor advances, employee dues, operational liabilities) deployable by December 2025, Rs. 100 lakhs for future funding spread over 6-12 months covering MARSAPI Lifesciences acquisition integration, a pilot R&D facility at Belapur, product launches for two bio-formulations, and initial entry into nutraceuticals and soil-health products, and Rs. 15.29 lakhs for general corporate purposes including ERP upgrade and statutory dues. The company has committed to submit all quotations, invoices, and utilization reports to BSE under Regulation 32 monitoring.
The disclosure removes any debt-repayment overhang from the preferential issue and signals that fresh capital will be deployed into growth areas such as the MARSAPI acquisition, R&D, and nutraceutical/soil-health expansion. For shareholders, this means the Rs. 4.29 crore raise is being framed as a pure growth and working-capital exercise, though the small size of the issue and absence of debt deleveraging means limited immediate boost to the stock; investors will watch execution of the MARSAPI integration and the Belapur R&D rollout over the next 6-12 months.